Children's Oncology Group
childrensoncologygroup.orgTotal trials
442
Active
77
Phase 3
111
Total enrollment
337,248
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 40 of 100 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| cyclophosphamide | — | — | 100 | ||||
| vincristine sulfate | — | — | 93 | ||||
| etoposide | — | — | 79 | ||||
| cytarabine | — | — | 60 | ||||
| carboplatin | — | — | 42 | ||||
| doxorubicin hydrochloride | — | — | 62 | ||||
| Vincristine | — | — | 11 | ||||
| Dactinomycin | — | — | — | — | 18 | ||
| methotrexate | — | — | 57 | ||||
| Calaspargase Pegol | — | — | — | — | 6 | ||
| Cisplatin | — | — | 34 | ||||
| Doxorubicin | — | — | — | 6 | |||
| Irinotecan | — | — | — | 6 | |||
| daunorubicin hydrochloride | — | — | 30 | ||||
| ifosfamide | — | — | 27 | ||||
| pegaspargase | — | — | 25 | ||||
| thioguanine | — | — | — | 24 | |||
| prednisone | — | — | 34 | ||||
| dexamethasone | — | — | 29 | ||||
| leucovorin calcium | — | — | 27 | ||||
| Prednisolone | — | — | 8 | ||||
| irinotecan hydrochloride | — | — | — | 13 | |||
| Thiotepa | — | — | — | 13 | |||
| sargramostim | — | — | — | — | 12 | ||
| dexrazoxane hydrochloride | — | — | — | 11 | |||
| Isotretinoin | — | — | — | 11 | |||
| mitoxantrone hydrochloride | — | — | — | 8 | |||
| Asparaginase Erwinia chrysanthemi | — | — | — | — | 3 | ||
| Dinutuximab | — | — | — | — | 3 | ||
| filgrastim | — | — | 70 | ||||
| therapeutic hydrocortisone | — | — | 15 | ||||
| Melphalan | — | — | — | 13 | |||
| methylprednisolone | — | — | — | — | 9 | ||
| Lomustine | — | — | — | 7 | |||
| Busulfan | — | — | — | 7 | |||
| vinorelbine tartrate | — | — | — | — | 7 | ||
| Topotecan | — | — | — | — | 2 | ||
| Inotuzumab Ozogamicin | — | — | — | — | 2 | ||
| Fludarabine | — | — | — | — | 2 | ||
| mercaptopurine | — | — | 29 |
60 more active programs hidden
Next readouts
- 2014-12-31
- 2015-10-06
- 2016-06-30
- 2016-12-31
- 2019-06-30
- 2020-10-31
- 2022-06-30
- 2022-09-30
- 2023-06-30
- 2024-06-30
Top conditions
- Leukemia96
- Neuroblastoma37
- Sarcoma37
- Lymphoma30
- Unspecified Childhood Solid Tumor, Protocol Specific22
- Acute Lymphoblastic Leukemia18
- Recurrent Neuroblastoma15
- Kidney Cancer14
Frequently asked questions about Children's Oncology Group
- How many clinical trials does Children's Oncology Group have on ClinicalTrials.gov?
- Children's Oncology Group is listed as the lead sponsor on 442 clinical trials in ClinicalTrials.gov, 77 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Children's Oncology Group's trials are in Phase 3?
- 111 of Children's Oncology Group's trials are in Phase 3, spread across 100 active drug programs.
- What therapeutic areas does Children's Oncology Group focus on?
- Children's Oncology Group's most-studied conditions on ClinicalTrials.gov are Leukemia, Neuroblastoma, Sarcoma, Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific.
- When are Children's Oncology Group's next clinical trial readouts?
- Children's Oncology Group has 10 upcoming primary-completion readouts tracked here; the soonest is “Vincristine, Dactinomycin, and Doxorubicin With or Without Radiation Therapy or Observation Only in Treating Younger Patients Who Are Undergoing Surgery for Newly Diagnosed Stage I, Stage II, or Stage III Wilms' Tumor”, expected around 2014-12-31.